MENU

Anti-fibrotic materials for immunoprotected cell-based therapies

Presented at: Bioprocessing 2021
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Cell encapsulation within semi-permeable devices represents a local immunoisolation strategy for cell-based therapies without the need for systemic immunosuppression. The encapsulation system allows for the diffusion of nutrients into the device which are important for cell survival, and the therapeutic payload produced by the cells to diffuse out in order to regulate the disease of choice. The barrier provided by the semi-permeable membrane prevents the entrance of immune cells that would otherwise destroy the therapeutic cells. For some time, encapsulation strategies have been applied to insulin producing islets of Langerhans transplantation and have shown long-term diabetes correction in many rodent models. However, these same strategies have failed when applied to a small number of clinical trials with diabetic patients. The foreign body response (FBR) to the biomaterials comprising the devices has been the major issue when testing in larger animal models. FBR results in the deposition of a dense ECM and cellular network covering the devices that restricts nutrition of the cells inside and compromises viability. Our lab is developing novel biomaterials and drug delivery strategies that can resist the foreign body response and fibrosis of implantable materials. Without fibrosis covering these encapsulation devices, free nutritional exchange for the therapeutic cells inside ensures continued secretion of their therapeutic payload for regulation of the disease of interest. This talk will discuss the discovery of a number of immune modulatory materials that have been developed in the Anderson/Langer lab that can reduce fibrotic activation and can lead to the protection of allogeneic islets in non-human primates for up to 4 months without any immune suppression.

Learning Objectives:

1. What is the major contributor to the failure of immunoisolated cell therapy devices in patients

2. Identify key immune cell types for immunomodulatory biomaterials


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
Loading Comments...
Show Resources